CNR1 and obesity due to melanocortin 4 receptor deficiency: Peripherally restricted CB1R inverse agonists (Cinar et al., 2020) and CB1R blocking antibodies show promising anti-obesity effects and are under early-stage clinical development (Dao and François, 2021).